- Home
- PYPD vs RNTX Comparison
PYPD vs RNTX Comparison
Compare PYPD & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- RNTX
- Stock Information
- Founded
- PYPD 2008
- RNTX 2001
- Country
- PYPD Israel
- RNTX United States
- Employees
- PYPD N/A
- RNTX N/A
- Industry
- PYPD Medical/Dental Instruments
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- RNTX Health Care
- Exchange
- PYPD Nasdaq
- RNTX Nasdaq
- Market Cap
- PYPD 36.0M
- RNTX 40.3M
- IPO Year
- PYPD 2020
- RNTX N/A
- Fundamental
- Price
- PYPD $3.45
- RNTX $1.54
- Analyst Decision
- PYPD Strong Buy
- RNTX
- Analyst Count
- PYPD 5
- RNTX 0
- Target Price
- PYPD $11.40
- RNTX N/A
- AVG Volume (30 Days)
- PYPD 1.4M
- RNTX 36.6K
- Earning Date
- PYPD 08-13-2025
- RNTX 08-13-2025
- Dividend Yield
- PYPD N/A
- RNTX N/A
- EPS Growth
- PYPD N/A
- RNTX N/A
- EPS
- PYPD N/A
- RNTX N/A
- Revenue
- PYPD N/A
- RNTX N/A
- Revenue This Year
- PYPD N/A
- RNTX N/A
- Revenue Next Year
- PYPD N/A
- RNTX N/A
- P/E Ratio
- PYPD N/A
- RNTX N/A
- Revenue Growth
- PYPD N/A
- RNTX N/A
- 52 Week Low
- PYPD $2.30
- RNTX $1.33
- 52 Week High
- PYPD $4.42
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- PYPD 53.89
- RNTX N/A
- Support Level
- PYPD $3.42
- RNTX N/A
- Resistance Level
- PYPD $3.57
- RNTX N/A
- Average True Range (ATR)
- PYPD 0.18
- RNTX 0.00
- MACD
- PYPD -0.03
- RNTX 0.00
- Stochastic Oscillator
- PYPD 52.55
- RNTX 0.00
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.